Back to News
Apr 22, 2026 4:00 AM

Samsung Biologics Reports First Quarter 2026 Financial Results

Recorded Q1'26 revenue of KRW 1,257 billion and operating profit of KRW 581 billion

Performance driven by full utilization across Plants 1 through 4 and robust operational execution

Strengthened the foundations for future growth through U.S. expansion and strategic partnerships

INCHEON, South Korea, April 22, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026.

"In the first quarter, Samsung Biologics delivered stable growth, supported by consistent execution across our manufacturing network and continued demand from clients," said John Rim, President and CEO of Samsung Biologics. "With full operations in plants at our Bio Campus I and Plant 5 ramp-up underway, we are further strengthening manufacturing readiness and service capacity to support evolving client needs. As our global footprint continues to expand, we remain focused on quality excellence, operational consistency, and strategic investment to support sustainable long-term growth."

Financial Highlights

In the first quarter of 2026, Samsung Biologics reported revenue of KRW 1,257 billion and operating profit of KRW 581 billion. Performance was mainly driven by full utilization across Plants 1 through 4 and continued project execution.